Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JUDITH L WHITE

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1316940018
CMS profile
14471
Location
KINGSPORT, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$485.12

28 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $334.95 19
Food and Beverage $150.17 9

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Eli Lilly and Company $485.12 28

Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JUDITH L WHITE

NPI 1316940018 · CMS profile ID 14471

Allopathic & Osteopathic Physicians / Internal Medicine

KINGSPORT, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1316940018?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JUDITH L WHITE, NPI 1316940018, CMS profile ID 14471. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1316940018?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JUDITH L WHITE, NPI 1316940018, CMS profile ID 14471. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1316940018?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JUDITH L WHITE, NPI 1316940018, CMS profile ID 14471, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1316940018?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

28 matching records · $485.12 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 28 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–28 of 28.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eli Lilly and Company $0.9808/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657925349 CMS
Eli Lilly and Company $2.0308/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657925351 CMS
Eli Lilly and Company $0.9808/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657925353 CMS
Eli Lilly and Company $10.2008/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657928825 CMS
Eli Lilly and Company $6.9508/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657928827 CMS
Eli Lilly and Company $3.0608/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657928829 CMS
Eli Lilly and Company $7.5108/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657928831 CMS
Eli Lilly and Company $7.5208/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657928833 CMS
Eli Lilly and Company $17.0308/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657932257 CMS
Eli Lilly and Company $21.0008/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657932259 CMS
Eli Lilly and Company $21.7608/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657932261 CMS
Eli Lilly and Company $3.0608/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657932263 CMS
Eli Lilly and Company $0.9808/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657932265 CMS
Eli Lilly and Company $0.9808/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657932267 CMS
Eli Lilly and Company $2.0308/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657932269 CMS
Eli Lilly and Company $9.4508/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657935631 CMS
Eli Lilly and Company $9.1808/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657942523 CMS
Eli Lilly and Company $10.2008/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657942525 CMS
Eli Lilly and Company $51.0008/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657945957 CMS
Eli Lilly and Company $15.3008/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657945959 CMS
Eli Lilly and Company $51.0008/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657945961 CMS
Eli Lilly and Company $84.0008/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657949343 CMS
Eli Lilly and Company $4.4608/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657949345 CMS
Eli Lilly and Company $128.0008/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657949347 CMS
Eli Lilly and Company $9.1808/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657949349 CMS
Eli Lilly and Company $4.0308/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728304149 CMS
Eli Lilly and Company $2.0308/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728304477 CMS
Eli Lilly and Company $1.2208/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728304479 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $485.12 28
PY2021 $2,163.83 6
PY2022 $51.76 3
PY2024 $1,672.68 17

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $640,741.74 27
PY2024 Principal investigator $267,189.88 19
PY2023 Recipient $98.80 1
PY2023 Principal investigator $96,720.88 105
PY2022 Recipient $85.00 1
PY2022 Principal investigator $1,700,193.53 16,257
PY2021 Recipient $242.50 1
PY2021 Principal investigator $910,699.42 50
PY2020 Recipient $1,336.87 14
PY2020 Principal investigator $850,450.68 67
PY2019 Principal investigator $1,175,554.95 90

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

90 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan Inc. $6,118.24 12/31/2019 Non-covered Recipient Entity
COMPASS RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670122805
Principal investigator 1 Allergan Inc. $156,299.76 12/31/2019 Non-covered Recipient Entity
COMPASS RESEARCH LLC
AURORA A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 670127943
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $742.62 12/31/2019 Non-covered Recipient Entity
SYNARC INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639740061
Principal investigator 1 Allergan Inc. $700.00 12/17/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670115941
Principal investigator 1 Allergan Inc. $45,071.80 12/17/2019 Non-covered Recipient Entity
COMPASS RESEARCH LLC
AURORA A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 670116443
Principal investigator 1 Nevro Corp. $1,800.00 12/05/2019 Non-covered Recipient Entity
Compass Research, LLC
Chronic Peripheral Polyneuropathy Randomized Trial No dispute reported 06/30/2026 679562663
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,872.42 11/30/2019 Non-covered Recipient Entity
SYNARC INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 673560589
Principal investigator 1 Nevro Corp. $142,950.58 11/21/2019 Non-covered Recipient Entity
Compass Research, LLC
Chronic Peripheral Polyneuropathy Randomized Trial No dispute reported 06/30/2026 679562627
Principal investigator 1 Allergan Inc. $327.00 11/12/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670095389
Principal investigator 1 Allergan Inc. $86.00 11/12/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670095573
Principal investigator 1 Nevro Corp. $6,395.00 11/07/2019 Non-covered Recipient Entity
Compass Research, LLC
Chronic Peripheral Polyneuropathy Randomized Trial No dispute reported 06/30/2026 679562633
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $24,218.24 10/31/2019 Non-covered Recipient Entity
SYNARC INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 673560587
Principal investigator 1 Allergan Inc. $345.00 10/22/2019 Non-covered Recipient Entity
COMPASS RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670088777
Principal investigator 1 Allergan Inc. $13,000.00 10/22/2019 Non-covered Recipient Entity
COMPASS RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670088977
Principal investigator 1 Allergan Inc. $5,479.03 10/17/2019 Non-covered Recipient Entity
COMPASS RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670086323
Principal investigator 1 Allergan Inc. $3,059.00 10/15/2019 Non-covered Recipient Entity
COMPASS RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670085705
Principal investigator 1 Nevro Corp. $3,545.00 10/10/2019 Non-covered Recipient Entity
Compass Research, LLC
Chronic Peripheral Polyneuropathy Randomized Trial No dispute reported 06/30/2026 679562657
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,153.44 09/30/2019 Non-covered Recipient Entity
SYNARC INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 673560585
Principal investigator 1 Allergan Inc. $9,074.59 09/24/2019 Non-covered Recipient Entity
COMPASS RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670079473
Principal investigator 1 Allergan Inc. $18,904.24 09/19/2019 Non-covered Recipient Entity
COMPASS RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670077709
Principal investigator 1 Allergan Inc. $1,446.85 09/18/2019 Non-covered Recipient Entity
COMPASS RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670076826
Principal investigator 1 Nevro Corp. $9,395.00 09/17/2019 Non-covered Recipient Entity
Compass Research, LLC
Chronic Peripheral Polyneuropathy Randomized Trial No dispute reported 06/30/2026 679562647
Principal investigator 1 Allergan Inc. $86.00 09/05/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670072935
Principal investigator 1 Nevro Corp. $4,500.00 09/05/2019 Non-covered Recipient Entity
Compass Research, LLC
Chronic Peripheral Polyneuropathy Randomized Trial No dispute reported 06/30/2026 679562643
Principal investigator 1 Allergan Inc. $86.00 09/03/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670071921
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $21,658.09 08/31/2019 Non-covered Recipient Entity
SYNARC INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639740059
Principal investigator 1 Allergan Inc. $13,000.00 08/27/2019 Non-covered Recipient Entity
COMPASS RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670069951
Principal investigator 1 Allergan Inc. $575.00 08/27/2019 Non-covered Recipient Entity
COMPASS RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670070109
Principal investigator 1 Allergan Inc. $16,774.15 08/22/2019 Non-covered Recipient Entity
COMPASS RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670067917
Principal investigator 1 Allergan Inc. $1,446.85 08/14/2019 Non-covered Recipient Entity
COMPASS RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670065505
Principal investigator 1 Nevro Corp. $2,390.00 08/02/2019 Non-covered Recipient Entity
Compass Research, LLC
Chronic Peripheral Polyneuropathy Randomized Trial No dispute reported 06/30/2026 679562623
Principal investigator 1 Nevro Corp. $1,169.00 07/23/2019 Non-covered Recipient Entity
Western Institutional Review
Chronic Peripheral Polyneuropathy Randomized Trial No dispute reported 06/30/2026 679560827
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $956.00 07/19/2019 Non-covered Recipient Entity
Compass Research LLC
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629161261
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $523.00 07/19/2019 Non-covered Recipient Entity
Compass Research LLC
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629161575
Principal investigator 1 Allergan Inc. $3,872.20 07/15/2019 Non-covered Recipient Entity
COMPASS RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670057135
Principal investigator 1 Allergan Inc. $14,218.65 07/09/2019 Non-covered Recipient Entity
COMPASS RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670055413
Principal investigator 1 Nevro Corp. $1,472.80 07/03/2019 Non-covered Recipient Entity
Compass Research, LLC
Chronic Peripheral Polyneuropathy Randomized Trial No dispute reported 06/30/2026 679562605
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,536.53 06/30/2019 Non-covered Recipient Entity
SYNARC INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639740057
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $820.00 06/24/2019 Non-covered Recipient Entity
Compass Research LLC
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629162825
Principal investigator 1 Allergan Inc. $23,100.00 06/18/2019 Non-covered Recipient Entity
COMPASS RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670051807
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $51.00 06/17/2019 Non-covered Recipient Entity
Compass Research LLC
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629159049
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,733.00 06/17/2019 Non-covered Recipient Entity
Compass Research LLC
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629159361
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $350.00 06/17/2019 Non-covered Recipient Entity
Compass Research LLC
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629159679
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,733.00 06/17/2019 Non-covered Recipient Entity
Compass Research LLC
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629159995
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,733.00 06/17/2019 Non-covered Recipient Entity
Compass Research LLC
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629160313
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $958.00 06/17/2019 Non-covered Recipient Entity
Compass Research LLC
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629160945
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $958.00 06/17/2019 Non-covered Recipient Entity
Compass Research LLC
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629161889
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $120.00 06/17/2019 Non-covered Recipient Entity
Compass Research LLC
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629162513
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,057.00 06/17/2019 Non-covered Recipient Entity
Compass Research LLC
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629163137
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,784.00 06/17/2019 Non-covered Recipient Entity
Compass Research LLC
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629163757
Principal investigator 1 Nevro Corp. $6,960.00 06/12/2019 Non-covered Recipient Entity
Compass Research, LLC
Chronic Peripheral Polyneuropathy Randomized Trial No dispute reported 06/30/2026 679562615
Principal investigator 1 Allergan Inc. $7,700.00 06/11/2019 Non-covered Recipient Entity
COMPASS RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670051105
Principal investigator 1 Allergan Inc. $500.00 06/11/2019 Non-covered Recipient Entity
COMPASS RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670051325
Principal investigator 1 Merck Sharp & Dohme Corporation $1,950.00 06/07/2019 Non-covered Recipient Entity
HOLSTON MEDICAL GROUP PC
TECOS A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Mono- or Dual Combination Oral Antihyperglycemic Therapy No dispute reported 06/30/2026 691350234
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,495.93 05/31/2019 Non-covered Recipient Entity
SYNARC INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639740055
Principal investigator 1 Allergan Inc. $4,131.55 05/28/2019 Non-covered Recipient Entity
COMPASS RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670048275
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $470.00 05/15/2019 Non-covered Recipient Entity
Compass Research LLC
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629160631
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $809.00 05/15/2019 Non-covered Recipient Entity
Compass Research LLC
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629162201
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,101.00 05/15/2019 Non-covered Recipient Entity
Compass Research LLC
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629163447
Principal investigator 1 Nevro Corp. $848.00 05/10/2019 Non-covered Recipient Entity
Western Institutional Review
Chronic Peripheral Polyneuropathy Randomized Trial No dispute reported 06/30/2026 679560819
Principal investigator 1 Allergan Inc. $13,000.00 05/09/2019 Non-covered Recipient Entity
COMPASS RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670044321
Principal investigator 1 Allergan Inc. $1,919.00 05/07/2019 Non-covered Recipient Entity
COMPASS RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670043567
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31,514.12 04/30/2019 Non-covered Recipient Entity
SYNARC INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639740053
Principal investigator 1 Allergan Inc. $12,105.85 04/25/2019 Non-covered Recipient Entity
COMPASS RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670041313
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $391.81 04/25/2019 Non-covered Recipient Entity
Bioclinica Research - Orlando
Phase IIB Study - F3 24 wk No dispute reported 06/30/2026 639758259
Principal investigator 1 Nevro Corp. $107,886.36 04/25/2019 Non-covered Recipient Entity
Compass Research, LLC
Chronic Peripheral Polyneuropathy Randomized Trial No dispute reported 06/30/2026 679562599
Principal investigator 1 Allergan Inc. $5,410.06 04/23/2019 Non-covered Recipient Entity
COMPASS RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670039757
Principal investigator 1 Allergan Inc. $8,500.00 04/23/2019 Non-covered Recipient Entity
COMPASS RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670040191
Principal investigator 1 Allergan Inc. $400.00 04/23/2019 Non-covered Recipient Entity
COMPASS RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670040599
Principal investigator 1 PFIZER INC. $27,947.05 04/02/2019 Non-covered Recipient Entity
Compass Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF A DOSE TITRATION REGIMEN FOR THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671622683
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $30,201.56 03/31/2019 Non-covered Recipient Entity
SYNARC INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639740051
Principal investigator 1 Allergan Inc. $14,449.12 03/28/2019 Non-covered Recipient Entity
COMPASS RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670034971
Principal investigator 1 Allergan Inc. $7,942.00 03/26/2019 Non-covered Recipient Entity
COMPASS RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670033659
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $2,320.00 03/15/2019 Non-covered Recipient Entity
COMPASS RESEARCH NORTH LLC ORLANDO
A Study to Evaluate the Efficacy and Safety of VX-150 in Treating Subjects with Pain Caused by Small Fiber Neuropathy No dispute reported 06/30/2026 686140373
Principal investigator 1 Nevro Corp. $1,500.00 03/07/2019 Non-covered Recipient Entity
Compass Research, LLC
Chronic Peripheral Polyneuropathy Randomized Trial No dispute reported 06/30/2026 679562610
Principal investigator 1 PFIZER INC. $48.00 03/01/2019 Non-covered Recipient Entity
COMPAS RESEARCH LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF A DOSE TITRATION REGIMEN FOR THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671638123
Principal investigator 1 Allergan Inc. $9,388.85 02/28/2019 Non-covered Recipient Entity
COMPASS RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670028049
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,707.23 02/28/2019 Non-covered Recipient Entity
SYNARC INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639740049
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $215.84 02/25/2019 Non-covered Recipient Entity
Bioclinica Research - Orlando
Phase IIB Study - F4 48 wk No dispute reported 06/30/2026 639758261
Principal investigator 1 Allergan Inc. $13,431.10 02/05/2019 Non-covered Recipient Entity
COMPASS RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670021679
Principal investigator 1 Eli Lilly and Company $6,002.10 02/04/2019 Non-covered Recipient Entity
COMPASS RESEARCH LLC
AN OPEN LABEL, LONG TERM, SAFETY STUDY OF LASMIDITAN 100 MG AND 200 MG IN THE ACUTE TREATMENT OF MIGRAINE GLADIATOR No dispute reported 06/30/2026 654290675
Principal investigator 1 PFIZER INC. $48.00 02/01/2019 Non-covered Recipient Entity
COMPAS RESEARCH LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF A DOSE TITRATION REGIMEN FOR THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671638173
Principal investigator 1 Eli Lilly and Company $348.70 01/31/2019 Non-covered Recipient Entity
COMPASS RESEARCH LLC
AN OPEN LABEL, LONG TERM, SAFETY STUDY OF LASMIDITAN 100 MG AND 200 MG IN THE ACUTE TREATMENT OF MIGRAINE GLADIATOR No dispute reported 06/30/2026 654293603
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,078.92 01/31/2019 Non-covered Recipient Entity
SYNARC INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639740047
Principal investigator 1 Allergan Inc. $500.00 01/22/2019 Non-covered Recipient Entity
COMPASS RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670018755
Principal investigator 1 MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC. $39,417.33 01/18/2019 Non-covered Recipient Entity
COMPASS RESEARCH LLC
An Open-label, Long Term Extension Study of MT-8554 in Postmenopausal Women Experiencing Moderate to Severe Vasomotor Symptoms Who Completed Study MT-8554-A01 No dispute reported 06/30/2026 705129487
Principal investigator 1 MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC. $41,299.48 01/15/2019 Non-covered Recipient Entity
COMPASS RESEARCH LLC
A Randomized, Double Blind, Placebo Controlled Study to Assess the Effect of MT-8554 on the Frequency and Severity of Vasomotor Symptoms in Postmenopausal Women No dispute reported 06/30/2026 705129541
Principal investigator 1 Allergan Inc. $2,165.05 01/03/2019 Non-covered Recipient Entity
COMPASS RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670014653
Principal investigator 1 Novartis Pharmaceuticals Corporation $164,758.86 01/01/2019 Non-covered Recipient Entity
ACCELERATED ENROLLMENT SOLUTIONS
A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED 2 PART ADAPTIVE DESIGN MULTICENTER 12 WEEK STUDY TO ASSESS SAFETY TOLERABILITY AND EFFICACY OF LJN452 IN PATIENTS WITH NON ALCOHOLIC STEATOHEPETATIS NASH No dispute reported 06/30/2026 640709367
Principal investigator 1 PFIZER INC. $48.00 01/01/2019 Non-covered Recipient Entity
COMPAS RESEARCH LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF A DOSE TITRATION REGIMEN FOR THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671638175